Caspase-3 as a therapeutic target for heart failure

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 3, 2013, Pages 255-263

  Yang, Bo ^a   Ye, Dewei ^a   Wang, Yu ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Apoptosis; Caspase inhibitor; Contractile function; Heart failure

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CASPASE 3; CASPASE 3 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT;

APOPTOSIS; DRUG TARGETING; HEART ASSIST DEVICE; HEART DISEASE; HEART FAILURE; HEART MUSCLE CELL; HUMAN; LEFT VENTRICULAR ASSISTED DEVICE; REVIEW;

ANIMALS; APOPTOSIS; CASPASE 3; CASPASE INHIBITORS; HEART FAILURE; HUMANS; MYOCYTES, CARDIAC;

EID: 84873888150     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.745513     Document Type: Review

References (113)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010;121(7):e46-e215
2. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93(9):1137-46
3. Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, et al. Characteristics and outcomes of patients with heart failure in general practices and hospitals. Circ J 2007;71(4):449-54
4. McMurray JJ, Pfeffer MA. Heart failure. Lancet 2005;365(9474):1877-89
5. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119(14):e391-479
6. Black HR. The burden of cardiovascular disease: following the link from hypertension to myocardial infarction and heart failure. Am J Hypertens 2003;16(9 Pt 2):4S-6S
7. Butler J. Primary prevention of heart failure. ISRN Cardiology 2012. [Epub ahead of print]
8. Mercer BN, Morais S, Cubbon RM, Kearney MT. Diabetes mellitus and the heart. Int J Clin Pract 2012;66(7):640-7
9. Velagaleti RS, Pencina MJ, Murabito JM, et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation 2008;118(20):2057-62
10. Goldberg LR, Jessup M. Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction. Circulation 2006;113(24):2851-60
11. Oka T, Komuro I. Molecular mechanisms underlying the transition of cardiac hypertrophy to heart failure. Circ J 2008;72(Suppl A):A13-16
12. Zannad F, Agrinier N, Alla F. Heart failure burden and therapy. Europace 2009;11(Suppl 5):v1-9
13. Mughal W, Kirshenbaum LA. Cell death signalling mechanisms in heart failure. Exp Clin Cardiol 2011;16(4):102-8
14. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med 1997;336(16):1131-41
15. Gill C, Mestril R, Samali A. Losing heart: the role of apoptosis in heart disease-a novel therapeutic target? FASEB J 2002;16(2):135-46
16. Anversa P, Leri A, Beltrami CA, et al. Myocyte death and growth in the failing heart. Lab Invest 1998;78(7):767-86
17. Narula J, Pandey P, Arbustini E, et al. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc Natl Acad Sci USA 1999;96(14):8144-9
18. Olivetti G, Quaini F, Sala R, et al. Acute myocardial infarction in humans is associated with activation of programmed myocyte cell death in the surviving portion of the heart. J Mol Cell Cardiol 1996;28(9):2005-16
19. Saraste A, Pulkki K, Kallajoki M, et al. Cardiomyocyte apoptosis and progression of heart failure to transplantation. Eur J Clin Invest 1999;29(5):380-6
20. Kang PM, Haunstetter A, Aoki H, et al. Morphological and molecular characterization of adult cardiomyocyte apoptosis during hypoxia and reoxygenation. Circ Res 2000;87(2):118-25
21. Mallat Z, Tedgui A, Fontaliran F, et al. Evidence of apoptosis in arrhythmogenic right ventricular dysplasia. N Engl J Med 1996;335(16):1190-6
22. Bing OH. Hypothesis: apoptosis may be a mechanism for the transition to heart failure with chronic pressure overload. J Mol Cell Cardiol 1994;26(8):943-8
23. Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation 2000;102(20 Suppl 4): IV14-23
24. Das M. Apoptosis as a therapeutic target in heart failure. American journal of physiology. Heart and circulatory physiology 2007;293(3):H1322-3
25. Kerr JF. History of the events leading to the formulation of the apoptosis concept. Toxicology 2002;181-182:471-4
26. Tucka J, Bennett M, Littlewood T. Cell death and survival signalling in the cardiovascular system. Front Biosci 2012;17:248-61
27. Chiong M, Wang ZV, Pedrozo Z, et al. Cardiomyocyte death: mechanisms and translational implications. Cell Death Dis 2011;2:e244
28. Ferri KF, Kroemer G. Organelle-specific initiation of cell death pathways. Nat Cell Biol 2001;3(11):E255-63
29. Mani K. Programmed cell death in cardiac myocytes: strategies to maximize post-ischemic salvage. Heart Fail Rev 2008;13(2):193-209
30. Soonpaa MH, Field LJ. Survey of studies examining mammalian cardiomyocyte DNA synthesis. Circ Res 1998;83(1):15-26
31. Whelan RS, Kaplinskiy V, Kitsis RN. Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Physiol 2010;72:19-44
32. Marin-Garcia J, Goldenthal MJ. Mitochondrial centrality in heart failure. Heart Fail Rev 2008;13(2):137-50
33. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91(4):479-89
34. Emoto Y, Manome Y, Meinhardt G, et al. Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells. EMBO J 1995;14(24):6148-56
35. Xue D, Shaham S, Horvitz HR. The Caenorhabditis elegans cell-death protein CED-3 is a cysteine protease with substrate specificities similar to those of the human CPP32 protease. Genes Dev 1996;10(9):1073-83
36. Porter AG, Janicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ 1999;6(2):99-104
37. Communal C, Sumandea M, de Tombe P, et al. Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci USA 2002;99(9):6252-6
38. Moretti A, Weig HJ, Ott T, et al. Essential myosin light chain as a target for caspase-3 in failing myocardium. Proc Natl Acad Sci USA 2002;99(18):11860-5
39. Masri C, Chandrashekhar Y. Apoptosis: a potentially reversible, meta-stable state of the heart. Heart Fail Rev 2008;13(2):175-9
40. Reed JC, Paternostro G. Postmitochondrial regulation of apoptosis during heart failure. Proc Natl Acad Sci USA 1999;96(14):7614-16
41. Kanoh M, Takemura G, Misao J, et al. Significance of myocytes with positive DNA in situ nick end-labeling (TUNEL) in hearts with dilated cardiomyopathy: not apoptosis but DNA repair. Circulation 1999;99(21):2757-64
42. Narula J, Arbustini E, Chandrashekhar Y, Schwaiger M. Apoptosis and the systolic dysfunction in congestive heart failure. Story of apoptosis interruptus and zombie myocytes. Cardiol Clin 2001;19(1):113-26
43. Narula J, Haider N, Arbustini E, Chandrashekhar Y. Mechanisms of disease: apoptosis in heart failure-seeing hope in death. Nat Clin Pract Cardiovasc Med 2006;3(12):681-8
44. Lee Y, Gustafsson AB. Role of apoptosis in cardiovascular disease. Apoptosis 2009;14(4):536-48
45. Gonzalez A, Ravassa S, Lopez B, et al. Apoptosis in hypertensive heart disease: a clinical approach. Curr Opin Cardiol 2006;21(4):288-94
46. Hofstra L, Liem IH, Dumont EA, et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 2000;356(9225):209-12
47. Rodriguez M, Lucchesi BR, Schaper J. Apoptosis in myocardial infarction. Ann Med 2002;34(6):470-9
48. Abbate A, Biondi-Zoccai GG, Bussani R, et al. Increased myocardial apoptosis in patients with unfavorable left ventricular remodeling and early symptomatic post-infarction heart failure. J Am Coll Cardiol 2003;41(5):753-60
49. Yamamoto S, Sawada K, Shimomura H, et al. On the nature of cell death during remodeling of hypertrophied human myocardium. J Mol Cell Cardiol 2000;32(1):161-75
50. Beltrami CA, Finato N, Rocco M, et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 1994;89(1):151-63
51. Guerra S, Leri A, Wang X, et al. Myocyte death in the failing human heart is gender dependent. Circ Res 1999;85(9):856-66
52. Narula J, Haider N, Virmani R, et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996;335(16):1182-9
53. Beltrami CA, Finato N, Rocco M, et al. The cellular basis of dilated cardiomyopathy in humans. J Mol Cell Cardiol 1995;27(1):291-305
54. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119(3):493-501
55. Hunter AL, Choy JC, Granville DJ. Detection of apoptosis in cardiovascular diseases. Methods Mol Med 2005;112:277-89
56. van Heerde WL, Robert-Offerman S, Dumont E, et al. Markers of apoptosis in cardiovascular tissues: focus on Annexin V. Cardiovasc Res 2000;45(3):549-59
57. Bott-Flugel L, Weig HJ, Uhlein H, et al. Quantitative analysis of apoptotic markers in human end-stage heart failure. Eur J Heart Fail 2008;10(2):129-32
58. McCarthy NJ, Evan GI. Methods for detecting and quantifying apoptosis. Curr Top Dev Biol 1998;36:259-78
59. Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature 2000;407(6805):784-8
60. Sosnovik DE, Nahrendorf M, Panizzi P, et al. Molecular MRI detects low levels of cardiomyocyte apoptosis in a transgenic model of chronic heart failure. Circ Cardiovasc Imaging 2009;2(6):468-75
61. Hickson J, Ackler S, Klaubert D, et al. Noninvasive molecular imaging of apoptosis in vivo using a modified firefly luciferase substrate, Z-DEVD-aminoluciferin. Cell Death Differ 2010;17(6):1003-10
62. Rodriguez M, Schaper J. Apoptosis: measurement and technical issues. J Mol Cell Cardiol 2005;38(1):15-20
63. Foo RS, Mani K, Kitsis RN. Death begets failure in the heart. J Clin Invest 2005;115(3):565-71
64. Mani K, Kitsis RN. Myocyte apoptosis: programming ventricular remodeling. J Am Coll Cardiol 2003;41(5):761-4
65. Bialik S, Geenen DL, Sasson IE, et al. Myocyte apoptosis during acute myocardial infarction in the mouse localizes to hypoxic regions but occurs independently of p53. J Clin Invest 1997;100(6):1363-72
66. Fliss H, Gattinger D. Apoptosis in ischemic and reperfused rat myocardium. Circ Res 1996;79(5):949-56
67. Wencker D, Chandra M, Nguyen K, et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 2003;111(10):1497-504
68. Wohlschlaeger J, Schmitz KJ, Schmid C, et al. Reverse remodeling following insertion of left ventricular assist devices (LVAD): a review of the morphological and molecular changes. Cardiovasc Res 2005;68(3):376-86
69. Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov 2002;1(2):111-21
70. Haider N, Narula N, Narula J. Apoptosis in heart failure represents programmed cell survival, not death, of cardiomyocytes and likelihood of reverse remodeling. J Card Fail 2002;8(6 Suppl):S512-17
71. Morissette MR, Rosenzweig A. Targeting survival signaling in heart failure. Curr Opin Pharmacol 2005;5(2):165-70
72. Deveraux QL, Roy N, Stennicke HR, et al.Ps block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 1998;17(8):2215-23
73. Chen Z, Chua CC, Ho YS, et al. Overexpression of Bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice. Am J Physiol Heart Circ Physiol 2001;280(5):H2313-20
74. Diwan A, Krenz M, Syed FM, et al. Inhibition of ischemic cardiomyocyte apoptosis through targeted ablation of Bnip3 restrains postinfarction remodeling in mice. J Clin Invest 2007;117(10):2825-33
75. Jeremias I, Kupatt C, Martin-Villalba A, et al. Involvement of CD95/Apo1/Fas in cell death after myocardial ischemia. Circulation 2000;102(8):915-20
76. Liu HR, Gao E, Hu A, et al. Role of Omi/HtrA2 in apoptotic cell death after myocardial ischemia and reperfusion. Circulation 2005;111(1):90-6
77. Adams JW, Sakata Y, Davis MG, et al. Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci USA 1998;95(17):10140-5
78. Yussman MG, Toyokawa T, Odley A, et al. Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. Nat Med 2002;8(7):725-30
79. Regula KM, Ens K, Kirshenbaum LA. Inducible expression of BNIP3 provokes mitochondrial defects and hypoxia-mediated cell death of ventricular myocytes. Circ Res 2002;91(3):226-31
80. Kubasiak LA, Hernandez OM, Bishopric NH, Webster KA. Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3. Proc Natl Acad Sci USA 2002;99(20):12825-30
81. Hirota H, Chen J, Betz UA, et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 1999;97(2):189-98
82. Chatterjee S, Stewart AS, Bish LT, et al. Viral gene transfer of the antiapoptotic factor Bcl-2 protects against chronic postischemic heart failure. Circulation 2002;106(12 Suppl 1):I212-17
83. Cacciapaglia F, Navarini L, Menna P, et al. Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues. Autoimmun Rev 2011;10(10):631-5
84. Iwatsubo K, Ishikawa Y. Therapeutic targets for heart failure: beyond beta-adrenergic and renin-angiotensin system blockade. Recent Pat Cardiovasc Drug Discov 2008;3(1):37-44
85. Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004;432(7016):466-72
86. Li Q, Li B, Wang X, et al. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest 1997;100(8):1991-9
87. Fazio S, Sabatini D, Capaldo B, et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996;334(13):809-14
88. Shah AM, Mann DL. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet 2011;378(9792):704-12
89. Scheubel RJ, Bartling B, Simm A, et al. Apoptotic pathway activation from mitochondria and death receptors without caspase-3 cleavage in failing human myocardium: fragile balance of myocyte survival? J Am Coll Cardiol 2002;39(3):481-8
90. Yaoita H, Maruyama Y. Intervention for apoptosis in cardiomyopathy. Heart Fail Rev 2008;13(2):181-91
91. Holly TA, Drincic A, Byun Y, et al. Caspase inhibition reduces myocyte cell death induced by myocardial ischemia and reperfusion in vivo. J Mol Cell Cardiol 1999;31(9):1709-15
92. Huang JQ, Radinovic S, Rezaiefar P, Black SC. In vivo myocardial infarct size reduction by a caspase inhibitor administered after the onset of ischemia. Eur J Pharmacol 2000;402(1-2):139-42
93. Yarbrough WM, Mukherjee R, Escobar GP, et al. Pharmacologic inhibition of intracellular caspases after myocardial infarction attenuates left ventricular remodeling: a potentially novel pathway. J Thorac Cardiovasc Surg 2003;126(6):1892-9
94. Yaoita H, Ogawa K, Maehara K, Maruyama Y. Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation 1998;97(3):276-81
95. Hayakawa Y, Chandra M, Miao W, et al. Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Galpha(q) transgenic mice. Circulation 2003;108(24):3036-41
96. Chatterjee S, Bish LT, Jayasankar V, et al. Blocking the development of postischemic cardiomyopathy with viral gene transfer of the apoptosis repressor with caspase recruitment domain. J Thorac Cardiovasc Surg 2003;125(6):1461-9
97. Li J, Billiar TR, Talanian RV, Kim YM. Nitric oxide reversibly inhibits seven members of the caspase family via S-nitrosylation. Biochem Biophys Res Commun 1997;240(2):419-24
98. Mannick JB, Hausladen A, Liu L, et al. Fas-induced caspase denitrosylation. Science 1999;284(5414):651-4
99. Condorelli G, Roncarati R, Ross J Jr, et al. Heart-targeted overexpression of caspase3 in mice increases infarct size and depresses cardiac function. Proc Natl Acad Sci USA 2001;98(17):9977-82
100. Philipp S, Pagel I, Hohnel K, et al. Regulation of caspase 3 and Fas in pressure overload-induced left ventricular dysfunction. Eur J Heart Fail 2004;6(7):845-51
101. Cai L, Li W, Wang G, et al. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 2002;51(6):1938-48
102. Chandrashekhar Y, Sen S, Anway R, et al. Long-term caspase inhibition ameliorates apoptosis, reduces myocardial troponin-I cleavage, protects left ventricular function, and attenuates remodeling in rats with myocardial infarction. J Am Coll Cardiol 2004;43(2):295-301
103. Mannick JB, Schonhoff C, Papeta N, et al. S-Nitrosylation of mitochondrial caspases. J Cell Biol 2001;154(6):1111-16
104. Yue TL, Wang C, Romanic AM, et al. Staurosporine-induced apoptosis in cardiomyocytes: a potential role of caspase-3. J Mol Cell Cardiol 1998;30(3):495-507
105. Ruetten H, Badorff C, Ihling C, et al. Inhibition of caspase-3 improves contractile recovery of stunned myocardium, independent of apoptosis-inhibitory effects. J Am Coll Cardiol 2001;38(7):2063-70
106. Balakumar P, Singh M. The possible role of caspase-3 in pathological and physiological cardiac hypertrophy in rats. Basic Clin Pharmacol Toxicol 2006;99(6):418-24
107. Balsam LB, Kofidis T, Robbins RC. Caspase-3 inhibition preserves myocardial geometry and long-term function after infarction. J Surg Res 2005;124(2):194-200
108. Grunenfelder J, Miniati DN, Murata S, et al. Upregulation of Bcl-2 through caspase-3 inhibition ameliorates ischemia/reperfusion injury in rat cardiac allografts. Circulation 2001;104(12 Suppl 1):I202-6
109. Grazette LP, Boecker W, Matsui T, et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol 2004;44(11):2231-8
110. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002;8(5):459-65
111. Leist M, Single B, Castoldi AF, et al. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 1997;185(8):1481-6
112. Elsasser A, Suzuki K, Schaper J. Unresolved issues regarding the role of apoptosis in the pathogenesis of ischemic injury and heart failure. J Mol Cell Cardiol 2000;32(5):711-24
113. Okamura T, Miura T, Takemura G, et al. Effect of caspase inhibitors on myocardial infarct size and myocyte DNA fragmentation in the ischemia-reperfused rat heart. Cardiovasc Res 2000;45(3):642-50